Emerging Immunotherapy Approaches for Treating Prostate Cancer

被引:20
作者
Meng, Lingbin [1 ]
Yang, Yuanquan [1 ]
Mortazavi, Amir [1 ]
Zhang, Jingsong [2 ]
机构
[1] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA
关键词
immunotherapy; prostate cancer; immune checkpoint inhibitors; bispecific antibodies; CAR T cells; vaccines; cytokines; immunotherapeutic combinations; CAR-T-CELLS; IMMUNE-CHECKPOINT; DOUBLE-BLIND; PHASE-III; PLUS DOCETAXEL; CLINICAL-TRIAL; SIPULEUCEL-T; TUMOR MICROENVIRONMENT; DNA VACCINE; ANTIGEN;
D O I
10.3390/ijms241814347
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunotherapy has emerged as an important approach for cancer treatment, but its clinical efficacy has been limited in prostate cancer compared to other malignancies. This review summarizes key immunotherapy strategies under evaluation for prostate cancer, including immune checkpoint inhibitors, bispecific T cell-engaging antibodies, chimeric antigen receptor (CAR) T cells, therapeutic vaccines, and cytokines. For each modality, the rationale stemming from preclinical studies is discussed along with outcomes from completed clinical trials and strategies to improve clinical efficacy that are being tested in ongoing clinical trials. Imperative endeavors include biomarker discovery for patient selection, deciphering resistance mechanisms, refining cellular therapies such as CAR T cells, and early-stage intervention were reviewed. These ongoing efforts instill optimism that immunotherapy may eventually deliver significant clinical benefits and expand treatment options for patients with advanced prostate cancer.
引用
收藏
页数:26
相关论文
共 186 条
[81]   Current understanding of CTLA-4: from mechanism to autoimmune diseases [J].
Hossen, Md Munnaf ;
Ma, Yanmei ;
Yin, Zhihua ;
Xia, Yuhao ;
Du, Jing ;
Huang, Jim Yi ;
Huang, Jennifer Jin ;
Zou, Linghua ;
Ye, Zhizhong ;
Huang, Zhong .
FRONTIERS IN IMMUNOLOGY, 2023, 14
[82]   Bispecific T-cell engagers for cancer immunotherapy [J].
Huehls, Amelia M. ;
Coupet, Tiffany A. ;
Sentman, Charles L. .
IMMUNOLOGY AND CELL BIOLOGY, 2015, 93 (03) :290-296
[83]   Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy [J].
Jiao, Shiping ;
Subudhi, Sumit K. ;
Aparicio, Ana ;
Ge, Zhongqi ;
Guan, Baoxiang ;
Miura, Yuji ;
Sharma, Padmanee .
CELL, 2019, 179 (05) :1177-+
[84]   Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma [J].
Kaehler, Katharina C. ;
Hauschild, Axel .
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 (04) :277-285
[85]   Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. [J].
Kantoff, Philip W. ;
Higano, Celestia S. ;
Shore, Neal D. ;
Berger, E. Roy ;
Small, Eric J. ;
Penson, David F. ;
Redfern, Charles H. ;
Ferrari, Anna C. ;
Dreicer, Robert ;
Sims, Robert B. ;
Xu, Yi ;
Frohlich, Mark W. ;
Schellhammer, Paul F. ;
Ahmed, T. ;
Amin, A. ;
Arseneau, J. ;
Barth, N. ;
Bernstein, G. ;
Bracken, B. ;
Burch, P. ;
Caggiano, V. ;
Chin, J. ;
Chodak, G. ;
Chu, F. ;
Corman, J. ;
Curti, B. ;
Dawson, N. ;
Deeken, J. F. ;
Dubernet, T. ;
Fishman, M. ;
Flanigan, R. ;
Gailani, F. ;
Garbo, L. ;
Gardner, T. ;
Gelmann, E. ;
George, D. ;
Godfrey, T. ;
Gomella, L. ;
Guerra, M. ;
Hall, S. ;
Hanson, J. ;
Israeli, R. ;
Jancis, E. ;
Jewett, M. A. S. ;
Kassabian, V. ;
Katz, J. ;
Klotz, L. ;
Koeneman, K. ;
Koh, H. ;
Kratzke, R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) :411-422
[86]   Mass spectrometry-based proteomics revealed Glypican-1 as a novel ADAM17 substrate [J].
Kawahara, Rebeca ;
Granato, Daniela Campos ;
Yokoo, Sami ;
Domingues, Romenia Ramos ;
Trindade, Daniel Maragno ;
Paes Leme, Adriana Franco .
JOURNAL OF PROTEOMICS, 2017, 151 :53-65
[87]   Preclinical Development of a WT1 Oral Cancer Vaccine Using a Bacterial Vector to Treat Castration-Resistant Prostate Cancer [J].
Kitagawa, Koichi ;
Gonoi, Reina ;
Tatsumi, Maho ;
Kadowaki, Masahide ;
Katayama, Takane ;
Hashii, Yoshiko ;
Fujisawa, Masato ;
Shirakawa, Toshiro .
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (05) :980-990
[88]   Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication [J].
Kloss, Christopher C. ;
Lee, Jihyun ;
Zhang, Aaron ;
Chen, Fang ;
Melenhorst, Jan Joseph ;
Lacey, Simon F. ;
Maus, Marcela V. ;
Fraietta, Joseph A. ;
Zhao, Yangbing ;
June, Carl H. .
MOLECULAR THERAPY, 2018, 26 (07) :1855-1866
[89]   Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy [J].
Kobold, Sebastian ;
Pantelyushin, Stanislav ;
Rataj, Felicitas ;
vom Berg, Johannes .
FRONTIERS IN ONCOLOGY, 2018, 8
[90]   Dual targeting strategies with bispecific antibodies [J].
Kontermann, Roland E. .
MABS, 2012, 4 (02) :182-197